| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4216102 | Revue des Maladies Respiratoires Actualités | 2011 | 7 Pages |
Abstract
Treatment of stage III N2 NSCLC remains controversy. No treatment strategy has proved superiority and different options have to been discussed: surgery followed by adjuvant chemotherapy, neoadjuvant chemotherapy followed by surgery or exclusive concomitant radio-chemotherapy. Several biomarkers are studied to better describe the indications of perioperative chemotherapy: recognize groups of patients with a worse prognosis and distinguish chemosensibility of the tumor.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
A.-M. Ruppert, L. Belmont, A. Lavolé, V. Gounant, J. Assouad, J. Cadranel, M. Wislez,